ESSA Pharma (EPI) Stock Rating Upgraded by Bloom Burton

ESSA Pharma (CVE:EPI) was upgraded by equities researchers at Bloom Burton from a “hold” rating to a “buy” rating in a research note issued on Thursday.

Shares of ESSA Pharma (CVE EPI) opened at C$0.30 on Thursday. ESSA Pharma has a 12 month low of C$0.22 and a 12 month high of C$4.60. The stock has a market cap of $8.72 and a PE ratio of -1.43.

COPYRIGHT VIOLATION WARNING: “ESSA Pharma (EPI) Stock Rating Upgraded by Bloom Burton” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.

Leave a Reply